How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics Inc (NASDAQ:MLNT) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($15.67) EPS for the quarter, missing analysts' consensus estimates of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to analyst estimates of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative trailing twelve-month return on equity of 101.29%.

When did Melinta Therapeutics' stock split?

Melinta Therapeutics's stock reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Melinta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA) , Clearside Biomedical (CLSD) , Chimerix (CMRX) , Aerie Pharmaceuticals (AERI) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Ocular Therapeutix (OCUL) , NVIDIA (NVDA) , Novavax (NVAX) and Nabriva Therapeutics (NBRV) .

NASDAQ:MLNT

Melinta Therapeutics (MLNT) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free MLNT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.35
▼
$0.50
52-Week Range: N/A

Volume: N/A
Average Volume: 713,628 shs
Market Capitalization: $6.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Melinta Therapeutics alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Melinta Therapeutics Stock (NASDAQ:MLNT)

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MLNT Stock News Headlines

February 28, 2024 | msn.com

FDA Requests Additional Data for Venatorx and Melinta's Antibiotic Combination

February 27, 2024 | msn.com

Promising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIs

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 23, 2024 | finance.yahoo.com

Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam

December 5, 2023 | msn.com

Cidara, Melinta announce publication of Rezzayo data in medical journal

November 9, 2023 | finance.yahoo.com

Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.

October 11, 2023 | finance.yahoo.com

Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023

October 2, 2023 | uk.finance.yahoo.com

Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

September 26, 2023 | thestreet.com

Melinta Therapeutics, Inc.

May 15, 2023 | finance.yahoo.com

Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada

March 1, 2023 | seekingalpha.com

Cidara Therapeutics Sheds Skin, Shifts To Immunotherapy

February 24, 2023 | finance.yahoo.com

BiVictriX Therapeutics reports "really exciting" BCX001 data

October 20, 2022 | technews.tmcnet.com

OptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired Event

July 27, 2022 | finance.yahoo.com

Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.

October 25, 2021 | finance.yahoo.com

Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development

September 20, 2021 | apnews.com

Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)

See More Headlines

Receive MLNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2019
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:MLNT
CUSIP: 15130J10
CIK: 1461993
Web: www.melinta.com
Phone: 908-617-1309
Fax: N/A
Employees: 290
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($17.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-157,190,000.00
Net Margins: -393.39%
Pretax Margin: N/A
Return on Equity: -101.29%
Return on Assets: -28.68%

Debt

Debt-to-Equity Ratio: 1.11
Current Ratio: 1.03
Quick Ratio: 0.72

Sales & Book Value

Annual Sales: $96.43 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $16.96 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 13,750,000
Free Float: N/A
Market Cap: $6.88 million
Optionable: Optionable
Beta: 4.16

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Erin M. Duffy (Age 51)
Chief Scientific Officer & Exec. VP
Mr. John H. Johnson (Age 61)
CEO & Director
Dr. Thomas A. Steitz
Co-Founder
Dr. Peter B. Moore Ph.D.
Co-Founder
Dr. William L. Jorgensen
Co-Founder

Key Competitors

View All Competitors

MLNT Stock Analysis - Frequently Asked Questions

How were Melinta Therapeutics' earnings last quarter?: Melinta Therapeutics Inc (NASDAQ:MLNT) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($15.67) EPS for the quarter, missing analysts' consensus estimates of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to analyst estimates of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative trailing twelve-month return on equity of 101.29%.
When did Melinta Therapeutics' stock split?: Melinta Therapeutics's stock reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
What other stocks do shareholders of Melinta Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Novavax (NVAX) and Nabriva Therapeutics (NBRV).

This page (NASDAQ:MLNT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Melinta Therapeutics (MLNT) Stock Price, News & Analysis

About Melinta Therapeutics Stock (NASDAQ:MLNT)

MLNT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

MLNT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info